Dana-Farber Cancer Institute

Articles

First Clinical Trial of “Memory Like” Natural Killer Cells in Ovarian Cancer Opens at Dana-Farber

November 18th 2024

Investigators are opening a trial to evaluate a novel type of immune cellular therapy in patients with recurrent, platinum-resistant ovarian cancer.

Two Dana-Farber Cancer Institute Faculty Members Elected to the National Academy of Medicine

November 1st 2024

David Pellman, MD, and Matthew Vander Heiden, MD, PhD of Dana-Farber Cancer Institute have been named to the National Academy of Medicine.

Rapid Blood Cancer Diagnostic Could Speed Decisions and Save Lives

October 28th 2024

Researchers at Dana-Farber Cancer Institute have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions.

Dana-Farber/Boston Children's Ranked Among the Best Pediatric Cancer Programs in the Nation for 18th Year in a Row

October 25th 2024

U.S. News & World Report has recognized Dana-Farber/Boston Children's Cancer and Blood Disorders Center as the #2 pediatric cancer program in the nation.

Dana-Farber Cancer Institute Delivers ‘Simple Immediate Impact’ to Patient Comfort Using Weighted Blankets

October 14th 2024

Dana-Farber Cancer Institute has used weighted blankets to aid in patient care.

Study Finds Doctors and Patients Interested in Environmental Impact of Health Care Decisions

October 9th 2024

In focus groups conducted in the US, doctors and patients expressed openness to considering environmental factors when discussing treatment options.

Cigall Kadoch, PhD, Wins Prestigious Blavatnik National Award

October 7th 2024

Cigall Kadoch, PhD, has been named as the Laureate of the Blavatnik National Awards for Young Scientists in the field of life sciences.

Criteria for Cancer Clinical Trials and Treatment Regimens Place Patients of African and Middle Eastern Ancestry at a Disadvantage Due to Natural Blood Test Variability, Study Finds

October 4th 2024

Clinical trials may be inappropriately excluding some people with "Duffy-null phenotype," a trait found in people of African or Middle Eastern descent.

ADC Found Effective Against Brain Metastases in Patients with HER2+ Breast Cancer

September 26th 2024

T-DXd shows substantial antitumor activity in brain metastases in patients with HER2-positive breast cancer in a major international clinical trial.

High-Dose Vitamin D3 Does Not Provide Benefit for Metastatic Colorectal Cancer

September 23rd 2024

The SOLARIS trial results suggest that high-dose vitamin D3 cannot be recommended as a treatment for patients with untreated metastatic colon cancer.

Dana-Farber President and CEO Laurie Glimcher, MD, Announces Her Plans to Step Down Capping a Highly Successful Tenure Marked with Discovery and Innovation

September 12th 2024

Laurie H. Glimcher, MD, announced today that she will step down as Dana-Farber Cancer Institute President and CEO on October 1, 2024, and will assume the title of President Emerita.

New Research Shows CDK5–Cyclin B1 Regulates Mitotic Fidelity

September 9th 2024

The study alters the existing paradigm that CDK1-Cyclin B1 is the only CDK-cyclin complex essential for all stages of mitosis.

New Research Offers Hope for Safer and More Effective Blood Stem Cell Transplants

September 6th 2024

Systematic identification of minor histocompatibility antigens informs outcomes after allogeneic stem cell transplantation.

Dana-Farber's Edward Chouchani selected as a Howard Hughes Medical Institute Investigator

August 7th 2024

Edward Chouchani, PhD, of Dana-Farber Cancer Institute, has been named a Howard Hughes Medical Institute Investigator.

Researchers Report First Effective Use of Immunotherapy for Most Common Subtype of Colorectal Cancer

July 9th 2024

Botensilimab plus balstilimab generated responses in relapsed/refractory microsatellite stable metastatic colorectal cancer.

Dana-Farber Cancer Institute Partners With Massachusetts Firefighters to Address Cancer Risks

July 6th 2024

Dana-Farber Cancer Institute is proud to announce the launch of the Direct Connect Partnership with Massachusetts Firefighters, addressing the heightened cancer risk faced by firefighters.

Anti-Inflammatory Drug Celecoxib Could Reduce Risk of Colon Cancer Recurrence For a Subset of Patients

July 1st 2024

A study found stage 3 colon cancer patients with PIK3CA mutations taking celecoxib post-surgery had longer survival and disease-free intervals.

Dana-Farber Researchers Uncover Disparities in Lived Experiences for Patients and Physicians

June 19th 2024

Dana-Farber Cancer Institute investigators have found that people experience discrimination in different ways and in various realms of cancer care.

Most Young Breast Cancer Survivors Can Have Children

June 7th 2024

Most young breast cancer survivors can go on to have children despite the effects of their lifesaving treatment, a new study shows.

New $15 Million Grant to Dana-Farber Scientists Supports Research into Innovative Approaches to Endometrial Cancer Treatment

May 10th 2024

Physician-scientists at Dana-Farber Cancer Institute have received a 5-year, $15 million Program Project Grant from the NCI for research in endometrial cancer